Description: In the U.S., the insurance industry is regulated by the individual states. Learn more about the National Association of Insurance Commissioners (NAIC), which reviews and proposes model laws and assesses emerging issues.

Description: Discover an update on recent developments affecting U.S. retirement plans, such as regulatory guidance, new legislative proposals, recent court cases and recent trends. Experienced pension actuaries will share their perspectives on these issues and the impact on plan sponsors.

Description: State regulators continue to focus on the emergence of private equity firms purchasing life insurance companies, supporting reinsurance transactions, and the growing trend in life companies owning more complex assets. Modeling of complex assets is also growing in focus to balance risk and return parameters in forward financial models and asset adequacy testing. Hear from actuaries, regulators and rating agencies as they present the latest developments for the future of the intersection of private equity and life insurance companies and the potential for new regulatory guidance.

Description: Investigate the concept of value annuities and the potential cost-effective differences when compared to traditional annuities by attending this webcast. Value annuities are an alternative lifetime income solution where longevity and investment risks are born by a pool of annuitants rather than a centralized insurer. Join this webcast for a closer look at the practicalities of designing and administering a value pool. There will also be a focus on the legislative, regulator and supervisory implications.

Description: Gene therapy is a quickly evolving field and will continue to grow as a risk concern for many health plans, stop loss insurers and reinsurers. Currently, there are only two approved gene therapies in the U.S., but that number is expected to escalate starting in the fall of 2022. Revisit the experience plans have had with the first two gene therapies, discuss plan design and network considerations in light of gene therapy, and discuss the actual composition of the near-term pipeline along with a range of modeled financial impacts and considerations for payers.

Description: Learn about the climate-related risks and opportunities that are relevant to life insurers. Additionally, you will also discover an overview of key regulatory drivers around the globe that will require life insurers to take action in the near future.

Description: This article provides a basic introduction to the taxation of qualified annuities held in qualified retirement plans and IRAs. The article has been updated for the SECURE Act and the SECURE 2.0 Act. The article describes the basic types of employer-based plans, provides of overview of the taxation of contributions and benefits when annuities are held in connection with plans and IRAs, explains the required minimum distribution rules, and offers a brief introduction to recent legislation impacting qualified annuities.

Description: Discussion of recent developments in the taxation of noncoordinated benefits such as fixed indemnity, hospital indemnity, and specified disease insurance policies. Developments include a recent Chief Counsel Advice Memorandum and proposed triagency rulemaking that would impact non coordinated benefits.

Description: A diverse panel of health actuaries will be available to answer any attendee questions. An ACA question, we have it covered! A valuation question, we will find a solution. A professionalism issue, we will make a ruling! A regulatory concern, we will help guide the way!! No question is off limits! There are no stupid questions!

Description: The National Association of Insurance Commissioners (NAIC) is in the middle of a project to change the real-world economic scenario generator (RW ESG) prescribed for principle-based reserve and capital calculations. Explore a brief summary of the NAIC's RW ESG project and gain a general overview of RW ESGs. Learn how RW ESGs impact principle-based reserve and capital levels, their potential impact on life insurance companies and consider differences between the currently prescribed RW ESG and the proposed RW ESG.